Redeye raises Medicover's base case to SEK 152 per share (previously SEK 127), our bull case to SEK 178 (previously SEK 150), and bear case to SEK 112. Despite initially being hard-hit by the covid-19 crisis in Q2, the company has succeeded to strongly increase revenues, EBITDA and EBIT. It has demonstrated adaptability, management capability and innovativeness, combined with the robustness and stability of a mature business.